242 related articles for article (PubMed ID: 35222540)
1. Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis.
Zhao Y; Wu J; Li L; Zhang H; Zhang H; Li J; Zhong H; Lei T; Jin Y; Xu B; Song Q
Front Genet; 2022; 13():820135. PubMed ID: 35222540
[No Abstract] [Full Text] [Related]
2. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
3. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
4. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive pan-cancer analysis identifies a novel glycolysis score and its hub genes as prognostic and immunological biomarkers.
Zheng D; Long S; Xi M
Transl Cancer Res; 2023 Oct; 12(10):2852-2874. PubMed ID: 37969385
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
[TBL] [Abstract][Full Text] [Related]
7. Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis.
Ye Y; Jiang H; Wu Y; Wang G; Huang Y; Sun W; Zhang M
Front Mol Biosci; 2022; 9():1001225. PubMed ID: 36213111
[No Abstract] [Full Text] [Related]
8. Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer.
Xu Q; Chen S; Hu Y; Huang W
Front Immunol; 2021; 12():711433. PubMed ID: 34512634
[TBL] [Abstract][Full Text] [Related]
9. IFN-α/β/IFN-γ/IL-15 pathways identify GBP1-expressing tumors with an immune-responsive phenotype.
Wang L; Wei Y; Jin Z; Liu F; Li X; Zhang X; Bai X; Jia Q; Zhu B; Chu Q
Clin Exp Med; 2024 May; 24(1):102. PubMed ID: 38758367
[TBL] [Abstract][Full Text] [Related]
10. Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model.
Zheng K; Hai Y; Chen H; Zhang Y; Hu X; Ni K
J Transl Med; 2024 Apr; 22(1):365. PubMed ID: 38632658
[TBL] [Abstract][Full Text] [Related]
11. The Prognostic and Immunological Value of Guanylate-Binding Proteins in Lower-Grade Glioma: Potential Markers or Not?
Liu Z; Sun J; Gong T; Tang H; Shen Y; Liu C
Front Genet; 2021; 12():651348. PubMed ID: 34759950
[TBL] [Abstract][Full Text] [Related]
12. Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy.
Tu Z; Li K; Ji Q; Huang Y; Lv S; Li J; Wu L; Huang K; Zhu X
BMC Cancer; 2023 Feb; 23(1):133. PubMed ID: 36759763
[TBL] [Abstract][Full Text] [Related]
13. Identification and quantification of immune infiltration landscape on therapy and prognosis in left- and right-sided colon cancer.
Guo JN; Chen D; Deng SH; Huang JR; Song JX; Li XY; Cui BB; Liu YL
Cancer Immunol Immunother; 2022 Jun; 71(6):1313-1330. PubMed ID: 34657172
[TBL] [Abstract][Full Text] [Related]
14. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
15. A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Aryl Hydrocarbon Receptor.
Mo Z; Li P; Cao Z; Zhang S
Front Immunol; 2021; 12():564948. PubMed ID: 34290693
[TBL] [Abstract][Full Text] [Related]
16. Correlation of PADI4, GBP1, miR-215, and TMB Expression Levels with Clinical Characteristics and Prognosis of Lung Cancer.
Chen J; Han Y; Zhao Y; Zhu W
Altern Ther Health Med; 2023 Jul; 29(5):238-241. PubMed ID: 37052970
[TBL] [Abstract][Full Text] [Related]
17. Integrated in silico analysis of LRP2 mutations to immunotherapy efficacy in pan-cancer cohort.
Li C; Ding Y; Zhang X; Hua K
Discov Oncol; 2022 Jul; 13(1):65. PubMed ID: 35834061
[TBL] [Abstract][Full Text] [Related]
18. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
19. MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients.
Wang G; Miao C; Mo L; Kahlert UD; Wu J; Ou M; Huang R; Feng R; Pang W; Shi W
Front Immunol; 2022; 13():1048503. PubMed ID: 36582246
[TBL] [Abstract][Full Text] [Related]
20. Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer.
Yu Y; Zhang W; Li A; Chen Y; Ou Q; He Z; Zhang Y; Liu R; Yao H; Song E
JAMA Netw Open; 2020 Apr; 3(4):e202149. PubMed ID: 32259264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
